BeiGene, Ltd. has fulfilled a long-cherished dream for its BTK inhibitor Brukinsa (zanubrutinib), which has outdone first-in-class competitor Imbruvica (ibrutinib) from AbbVie Inc./Johnson & Johnson in a head-to-head Phase III clinical trial in terms of both primary and secondary efficacy endpoints.
At a late-breaking session of the American Society of Hematology (ASH) annual meeting, held on 13 December in New Orleans,...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

